SCHEMBL468870

SCHEMBL468870

CC(=O)NCC(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTH P32929 1/20 0.44
EGLN1 Q9GZT9 2/20 0.43
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 1/20 0.41
PTGS2 P35354 1/20 0.41
FAAH O00519 5/20 0.40
ADRA1A P35348 1/20 0.40
KDM4E B2RXH2 2/20 0.39
SOST Q9BQB4 1/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
APEX1 P27695 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL468799 1.00 CTH (0.44) CTHEGLN1ALDH1A1MAPTTDP1
Aceturic Acid SCHEMBL5876 0.89
Aceturic Acid SCHEMBL42918 0.89 CTH (0.52) CTHEGLN1ALDH1A1MAPTTDP1
Aceturic Acid SCHEMBL10710298 0.87 CTH (0.50) CTHEGLN1ALDH1A1MAPTTDP1
Aceturic Acid SCHEMBL31614105 0.87
Aceturic Acid SCHEMBL31348252 0.87
Aceturic Acid SCHEMBL9438413 0.87
Aceturic Acid SCHEMBL9130077 0.87
Aceturic Acid SCHEMBL2120015 0.87
Aceturic Acid SCHEMBL27411062 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102358752-B GLP-1 and exendin related invention PHILIPPS UNIVERSITY MARBURG 2014-07-30 CN claimed
CN-102358752-A GLP-1 and exendin related invention PHILIPPS UNIVERSITY MARBURG 2012-02-22 CN claimed
CN-102304179-A With GLP-1 and the relevant invention of incretin analogue (exendin) UNIV MARBURG PHILIPPS 2012-01-04 CN claimed
CN-101010340-A Invention relating to GLP-1 and incretin analogue (exendin) UNIV MARBURG PHILIPPS (DE) 2007-08-01 CN claimed
EP-2311452-B2 Topical composition comprising n-acetyl glucosamine YU RUEY J (US) 2020-12-30 EP disclosed
US-20160280737-A1 ALKOXYSILANE DERIVATIVES OF N-ACYL AMINO ACIDS, N-ACYL DIPEPTIDES, AND N-ACYL TRIPEPTIDES, AND PARTICLES AND STABLE OIL-IN-WATER FORMULATIONS USING THE SAME GELEST TECHNOLOGIES, INC. 2016-09-29 US disclosed
US-9358200-B2 Alkoxysilane derivatives of N-acyl amino acids, N-acyl dipeptides, and N-acyl tripeptides, and particles and stable oil-in-water formulations using the same GELEST TECHNOLOGIES, INC. (US) 2016-06-07 US disclosed
EP-2311452-B9 Topical composition comprising n-acetyl glucosamine YU RUEY J (US) 2014-12-24 EP disclosed
CN-102358752-B GLP-1 and exendin related invention PHILIPPS UNIVERSITY MARBURG 2014-07-30 CN disclosed
US-RE44302-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-06-18 US disclosed
US-RE44017-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-02-19 US disclosed
CN-101010340-B Invention relating to GLP-1 and incretin analogue (exendin) UNIV MARBURG PHILIPPS 2012-11-28 CN disclosed
CN-1361766-A Tricyclic compounds having acyloxymethoxycarbonyl side chain SHIONOGI PHARMACEUTICAL & CO L (JP) 2002-07-31 CN disclosed
EP-1219606-A1 TRICYCLIC COMPOUNDS BEARING ACYLOXYMETHOXYCARBONYL PENDANTS SHIONOGI & CO., LTD. (JP) 2002-07-03 EP disclosed
EP-1143925-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2001-10-17 EP disclosed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US disclosed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 WO disclosed
EP-0726909-A1 N-ALKYL PEPTIDE CHELATE FORMERS, THEIR METAL COMPLEXES WITH RADIONUCLIDES, PROCESSES FOR PRODUCING THEM AND RADIO-PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) 1996-08-21 EP disclosed
WO-1995012610-A1 N-ALKYL PEPTIDE CHELATE FORMERS, THEIR METAL COMPLEXES WITH RADIONUCLIDES, PROCESSES FOR PRODUCING THEM AND RADIO-PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) 1995-05-11 WO disclosed
CN-1034545-A The protein and the glycoprotein of the metal-radioisotope labeling that is used to diagnose and treats NEORX CORP (US) 1989-08-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280737-A1 ALKOXYSILANE DERIVATIVES OF N-ACYL AMINO ACIDS, N-ACYL DIPEPTIDES, AND N-ACYL TRIPEPTIDES, AND PARTICLES AND STABLE OIL-IN-WATER FORMULATIONS USING THE SAME ASNS, NPPA, AADAT CTH 1772/4885EGLN1 2876/4885ALDH1A1 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.